2011

Safeguard Scientifics realized two significant deals in 2011, the first being the purchase of Advanced BioHealing by Shire plc (LSE: SHP, NASDAQ: SHPGY). Shire acquired Advanced BioHealing on the eve of pricing an IPO for $750 million, in cash, representing a 25 percent premium to the mid-point of the IPO pricing range and a 13x cash-on-cash return for Safeguard.

Advanced BioHealing’s Dermagraft® product was a bio-engineered living skin substitute to assist in restoring damaged tissue and support the body’s natural healing process, and had achieved significant market penetration as an FDA approved treatment for diabetic foot ulcers in the years leading up to Advanced BioHealing’s acquisition.